Want to join the conversation?
In the near term, $VRTX expects cash flow from product revenues to increase due to sales of cystic fibrosis drug Orkambi in the U.S. after receipt of FDA approval in July. $VRTX does not expect significant product revenue from Orkambi in 2015 from ex-U.S. markets.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?